Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 123Triple Negative Breast Neoplasms 22Lung Neoplasms 17Neoplasm Metastasis 12Carcinoma, Non-Small-Cell Lung 11Brain Neoplasms 9Pancreatic Neoplasms 8Ovarian Neoplasms 8Melanoma 8Prostatic Neoplasms 7Colonic Neoplasms 7Carcinoma, Renal Cell 7Breast Neoplasms, Male 7Stomach Neoplasms 6Meningeal Carcinomatosis 6Colorectal Neoplasms 6Carcinoma, Intraductal, Noninfiltrating 6Esophageal Neoplasms 5Carcinoma, Hepatocellular 5Anatomic Stage IV Breast Cancer AJCC v8 5Small Cell Lung Carcinoma 4Neoplasms 4Fallopian Tube Neoplasms 4Breast Carcinoma In Situ 4Anatomic Stage III Breast Cancer AJCC v8 4Uterine Cervical Neoplasms 3Thyroid Neoplasms 3Salivary Gland Neoplasms 3Rectal Neoplasms 3Inflammatory Breast Neoplasms 3

Interventions

Magnetic Resonance Spectroscopy 116-fluoroestradiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2/Neu Negative × Magnetic Resonance Spectroscopy × Breast × Clear all
NCT02398773 2026-04-21

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

National Cancer Institute (NCI)

Phase 2 Active not recruiting
99 enrolled
Breast

HER2/Neu Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡